Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 9 pages · English
Summary by 6ix AI
Recce Pharmaceuticals Ltd. has released its quarterly cash flow statement and operational highlights for the first quarter of the fiscal year. Additionally, the company received a substantial R&D tax incentive rebate, enhancing its financial position as it progresses with clinical trials. The filing also notes the completion of a share purchase plan, raising funds to support ongoing research and development activities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- License and Commercialisation Agreement in AUS/NZ for R327G
- Independent Review of Indonesian Phase 3 R327G Trial Data
- Notification regarding unquoted securities - RCE
- Amendments to Debt Facility with Avenue Capital Group
- Notice of Annual General Meeting/Proxy Form
Later from Recce Pharmaceuticals
- Application for quotation of securities - RCE
- Cleansing Notice
- Options Prospectus
- Retirement of Mr Alistair McKeough as Non-Executive Director
- AGM Presentation
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals